July 23rd 2024
AIC100 now has a regenerative medicine advanced therapy designation from the FDA for the treatment of recurrent anaplastic thyroid cancer.
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Tweet Chat Recap: Swegal Evaluates a Thyroid Cancer Case
August 31st 2022In an interview with Targeted Oncology following the tweet chat, Warren Swegal, MD, discussed the key takeaways from the discussion, including his thoughts on the case and what he hopes will be addressed in the future of the thyroid cancer space.
Read More
Increased Hemithyroidectomy Use in Thyroid Cancer Not Linked With ATA Guidelines
July 25th 2022Focused cancer centers increased hemithyroidectomy 2 years prior to the release of the newest American Thyroid Association guidelines. However, only community cancer program hospitals began to increase hemithyroidectomy utilization following release of guidelines.
Read More
EP. 3B: Factors Affecting Therapeutic Selection for NTRK Fusion-positive Thyroid Cancer
April 26th 2022In the second interview of the series, Marcia Brose, MD, PhD, reviews currently available therapies for NTRK fusion-positive thyroid cancer and highlights clinical factors affecting treatment decision-making.
Read More
EP. 3A: Treatment Considerations for Patients With TRK Fusion-positive Cancers
March 31st 2022In the second video of the series, Marcia Brose, MD, PhD, from the Sidney Kimmel Cancer Center – Jefferson Health shares key insights into factors affecting treatment decisions for patients with TRK fusion-positive cancers including the consideration of comorbidities and adverse event profiles.
Read More